Bio-Techne Corp

TECH: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
&?!LOCK|#@qLLOCK|$TyfP!J

Bio-Techne Earnings: Fourth-Quarter Results In-Line, but Volatile US Policy Is Hurting End Markets

Bio-Techne reported organic revenue growth of 3% for the fourth quarter of its fiscal 2025, which included 4% organic growth in protein sciences and 1% organic decline in diagnostics and spatial biology. Additionally, the company announced its divestiture of Exosome Diagnostics.

Sponsor Center